Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.46 |
| ▸ | ITGAV | P06756 | 17/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.41 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139143 | 0.89 | ITGB3 (0.49) | ITGB3ITGAVITGA2BCXCR4ITGB5 | |
| SCHEMBL20156048 | 0.78 | ITGAV (0.45) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL21281667 | 0.77 | CXCR4 (0.48) | ITGB3ITGAVCXCR4ITGB5ITGB6 | |
| SCHEMBL14610720 | 0.75 | ITGB3 (0.46) | ITGB3ITGAVITGA2BCXCR4ITGB5 | |
| SCHEMBL860427 | 0.74 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL20139711 | 0.74 | ITGB3 (0.48) | ITGB3ITGAVITGA2BCXCR4ITGB5 | |
| SCHEMBL21281634 | 0.74 | ITGB3 (0.48) | ITGB3ITGAVITGA2BCXCR4ITGB5 | |
| SCHEMBL21281724 | 0.73 | ITGAV (0.47) | ITGB3ITGAVITGA2BCXCR4ITGB6 | |
| SCHEMBL20153399 | 0.73 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL760607 | 0.72 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3538527-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | ITGB3 11/4885ITGAV 1/4885ITGA2B 12/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | ITGB3 11/4885ITGAV 1/4885ITGA2B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.